# 601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

> **NCT04922151** · PHASE2 · UNKNOWN · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Pathological Myopic Choroidal Neovascularization

## Interventions

- **DRUG:** 601
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT04922151
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-04
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-07-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04922151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04922151, "601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04922151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*